Point mutation of C-terminal region of CD20 molecule predicts rituximab-induced complement-dependent cytotoxicity and clinical response to rituximab in non-Hodgkin's lymphoma.

被引：0
|
作者：
Terui, Y.
Mishima, Y.
Mishima, Y.
Yokoyama, M.
Hatake, K.
Sugimura, N.
Kojima, K.
Sakurai, T.
Takeuchi, K.
机构：
[1] CIH, Tokyo, Japan
[2] Morinaga Milk Co, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：437S / 437S
页数：1
相关论文
共 47 条
  • [41] Historic deacetylase inhibitor promotes rituximab-induced apoptosis in non-Hodgkin's B-lymphoma cells by NF-kB-mediated Bcl-2[Bcl-XL downregulation and c-Myc degradation.
    Zhao, Weili
    Wang, Lan
    Liu, Yuanhua
    Yan, Jinsong
    Leboeuf, Christophe
    Janin, Anne
    Chen, Zhu
    Chen, Saijuan
    BLOOD, 2006, 108 (11) : 715A - 715A
  • [42] Chimeric anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase III randomized intergroup clinical trial
    Van Oers, M. H. J.
    Van Glabbeke, M.
    Teodorovic, I.
    Rozewicz, C.
    Klasa, R.
    Marcus, R. E.
    Wolf, M.
    Kimby, E.
    Hagenbeek, A.
    Kersten, M. J.
    ANNALS OF HEMATOLOGY, 2006, 85 : 47 - 47
  • [43] Chimeric anti-CD20 monoclonal antibody (Rituximab;Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase III randomized intergroup clinical trial.
    Van Oers, MHJ
    Glabbeke, MV
    Teodorovic, I
    Rozewicz, C
    Klasa, R
    Marcus, RE
    Wolf, M
    Kimby, E
    Hagenbeek, A
    BLOOD, 2005, 106 (11) : 107A - 107A
  • [44] Interleukin-2 (Proleukin®, Aldesleukin) augmentation of NK-mediated antibody dependent cellular cytotoxicity (ADCC) is associated with durable expansion of NKCD16+CD56+ immune effector cells in Non-Hodgkin's Lymphoma patients receiving rituximab
    Denis-Mize, K
    Tong, B
    Gluck, WL
    Yuen, AR
    Levine, AM
    Dayton, M
    Gockerman, JP
    Lucas, JB
    Milan, S
    Hurst, D
    Wilson, SE
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S43 - S43
  • [45] Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines:: Role in sensitization to chemotherapeutic drug-induced apoptosis
    Jazirehi, AR
    Huerta-Yepez, S
    Cheng, GH
    Bonavida, B
    CANCER RESEARCH, 2005, 65 (01) : 264 - 276
  • [46] In vitro synergistic anti-tumor activity by targeting TRAIL-R1 and CD20 antigen by combining HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) and rituximab monoclonal antibody against non-Hodgkin's lymphoma cells (NHL).
    Czuczman, MS
    Maddipatla, S
    Knight, J
    Hernandez-Ilizaliturri, FJ
    BLOOD, 2005, 106 (11) : 425A - 425A
  • [47] Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis
    Jazirehi, AR
    Gan, XH
    De Vos, S
    Emmanouilides, C
    Bonavida, B
    MOLECULAR CANCER THERAPEUTICS, 2003, 2 (11) : 1183 - 1193
12345